Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Share News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,830.00
Bid: 1,848.00
Ask: 1,860.00
Change: -38.00 (-2.03%)
Spread: 12.00 (0.649%)
Open: 1,830.00
High: 1,860.00
Low: 1,830.00
Prev. Close: 1,868.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Genus holds gloomy guidance as tough conditions persist

Thu, 22nd Feb 2024 08:42

(Sharecast News) - There were few surprises in Genus's interim results on Thursday after a detailed trading update from the animal genetics company just last week, as it reported a 31% drop in adjusted profits as expected.

Shares in Genus tanked 16% on 15 February after the company guided to full-year adjusted pre-tax profit of £58m, owing to challenging markets, well below the consensus forecast for a similar outcome from last year's £71.5m.

However, an absence of bad news its interim results has provided some reassurance, with shares rising 2.5% at 1,960p following the figures on Thursday morning.

In line with recent guidance, Genus said revenues were £334m in the six months to 31 December, down 5% on the previous year, which it described as "resilient" in a tough environment. At constant currency, revenues would have risen 1%.

Adjusted pre-tax profit was down 26% year-on-year on a reported basis at £29m due to weakness in China, particularly in its porcine business PIC and dairy/cattle unit ABS. In the latter specifically, demand for dairy genetics in China was hit by a double-digit decline in the dairy herd.

As mentioned last week, Genus is now undergoing a so-called "Value Acceleration Programme" in ABS to improve profitability and returns from investments.

"We have taken rapid action including initiating a comprehensive programme to accelerate the value delivery from our bovine operations," said chief executive Jorgen Kokke.

"We have also completed a strategic review of R&D activities. The company is benefitting from savings achieved in the first half and will benefit further in the second half of the year and into FY25, as we optimise resource allocation to best deliver our growth objectives."

The company said there was no change to the full-year guidance given last week, assuming that current market conditions persist for the rest of the year.

"We are seeing the positive impact of our actions to accelerate value delivery which will deliver further benefit in the second half and in subsequent years," Kokke said.

More News
12 Aug 2016 07:06

Genus suffers legal setback Stateside

(ShareCast News) - Genus suffered a legal setback Stateside as a US judge handed down a series of verdicts against the animal genetics specialist. The US District Court for Wisconsin ruled that two of Genus rival ST´s patents were valid and had been infringed and that ABS, a unit of Genus, had mater

Read more
11 Aug 2016 10:01

Genus and Sexing still battling over semen

(ShareCast News) - Animal genetics company Genus announced the first jury verdicts in its antitrust litigation against Inguran, operating as Sexing Technologies, relating to ABS's 'Genus Sexed Semen' processing technology. The FTSE 250 firm said that at the trial in the US District Court for the Wes

Read more
11 Aug 2016 07:45

Genus Says US Court Finds Against Inguran But Sees No Injury To Genus

Read more
4 Aug 2016 11:59

Thursday broker round-up

(ShareCast News) - Next: Goldman Sachs reiterates sell with a target price of 4800p. Standard Chartered: JP Morgan maintains overweight with a 800p target. Shire: JP Morgan reiterates overweight with a 6300p target. Genus: HSBC stays at buy with a 2200p target. Nichols: UBS keeps at buy with a ta

Read more
4 Jul 2016 08:37

BROKER RATINGS SUMMARY: Liberum Downgrades Property Stocks

Read more
4 Jul 2016 08:21

CORRECT (01/07): WINNERS & LOSERS SUMMARY

Read more
1 Jul 2016 15:58

LONDON MARKET CLOSE: Stocks Close Week After Brexit Vote On A High

Read more
1 Jul 2016 11:09

LONDON MARKET MIDDAY: Carney Boosts Stocks As easyJet Eyes Own Brexit

Read more
1 Jul 2016 09:11

WINNERS & LOSERS SUMMARY: Dignity And Genus Benefit From Upgrades

Read more
1 Jul 2016 08:51

BROKER RATINGS SUMMARY: Berenberg - Buy Dignity; Liberum - Buy Genus

Read more
1 Jul 2016 07:24

LONDON BRIEFING: Carney Lifts Brexit Blues With Policy Assurance

Read more
20 Jun 2016 09:25

ITV, Wolseley are Liberum's top-picks in case of Bremain, Brexit

(ShareCast News) - Depending on whether the UK finally decided to 'Remain' or 'Leave' then different London-listed securities were likelier to 'outperform' their respective sectors, Liberum said. The broker's 'top-picks' under a 'Remain', 'Leave' and 'Either way' scenario were, ITV, Wolseley and Bal

Read more
26 May 2016 14:30

FTSE 250 movers: Ibstock retreats as Pets at Home accelerates

(ShareCast News) - The FTSE 250 slipped further into the red late as Thursday wore on, despite having peeped its head above water around midday. Leading the index lower, shares in Ibstock subsided as the brick maker reported a slow start to the year for its UK clay business had lasted four months b

Read more
18 May 2016 09:49

Genus announces collaboration with Caribou Biosciences

(ShareCast News) - Genus announced a strategic collaboration with US-based Caribou Biosciences that will give the London-listed animal genetics group exclusive license to Caribou's gene editing technology platform. Caribou's CRISPR-Cas9 technology accurately targets and cuts DNA to produce precise a

Read more
18 May 2016 07:01

Genus Signs Gene Editing Platform Deal With Caribou Biosciences

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.